Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression.
Genetics/Genomics
Mood Disorders-Postpartum
Journal
The American journal of psychiatry
ISSN: 1535-7228
Titre abrégé: Am J Psychiatry
Pays: United States
ID NLM: 0370512
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
4
12
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Postpartum depression (PPD) is a common subtype of major depressive disorder (MDD) that is more heritable, yet is understudied in psychiatric genetics. The authors conducted meta-analyses of genome-wide association studies (GWASs) to investigate the genetic architecture of PPD. Meta-analyses were conducted on 18 cohorts of European ancestry (17,339 PPD cases and 53,426 controls), one cohort of East Asian ancestry (975 cases and 3,780 controls), and one cohort of African ancestry (456 cases and 1,255 controls), totaling 18,770 PPD cases and 58,461 controls. Post-GWAS analyses included 1) single-nucleotide polymorphism (SNP)-based heritability ([Formula: see text]), 2) genetic correlations between PPD and other phenotypes, and 3) enrichment of the PPD GWAS findings in 27 human tissues and 265 cell types from the mouse central and peripheral nervous system. No SNP achieved genome-wide significance in the European or the trans-ancestry meta-analyses. The [Formula: see text] of PPD was 0.14 (SE=0.02). Significant genetic correlations were estimated for PPD with MDD, bipolar disorder, anxiety disorders, posttraumatic stress disorder, insomnia, age at menarche, and polycystic ovary syndrome. Cell-type enrichment analyses implicate inhibitory neurons in the thalamus and cholinergic neurons within septal nuclei of the hypothalamus, a pattern that differs from MDD. While more samples are needed to reach genome-wide levels of significance, the results presented confirm PPD as a polygenic and heritable phenotype. There is also evidence that despite a high correlation with MDD, PPD may have unique genetic components. Cell enrichment results suggest GABAergic neurons, which converge on a common mechanism with the only medication approved by the U.S. Food and Drug Administration for PPD (brexanolone).
Identifiants
pubmed: 37849304
doi: 10.1176/appi.ajp.20230053
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
884-895Subventions
Organisme : NIMH NIH HHS
ID : K01 MH116413
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109528
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109532
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH120352
Pays : United States
Organisme : NIMH NIH HHS
ID : K08 MH127413
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH118223
Pays : United States
Organisme : NIMH NIH HHS
ID : R56 MH120736
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH123724
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH124873
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH125938
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH126358
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH077928
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH068036
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Dr. Choi has received an honorarium from